Vicore Pharma: Restoring lung function for IPF patients

Optimum Perspectives
12/12/2023 11 min Episodio 13
Vicore Pharma: Restoring lung function for IPF patients

Listen "Vicore Pharma: Restoring lung function for IPF patients"

Descargar episodio Ver en sitio original

Episode Synopsis

Hear Vicore Pharma’s CEO, Ahmed Mousa speak to Optimum's Richard Staines on their new treatment for Idiopathic Pulmonary Fibrosis (IPF), C21. It aims to improve available treatments for patients of IPF by halting the progression of fibrosis and has the aim of restoring lung function. Hosted on Acast. See acast.com/privacy for more information.

More episodes of the podcast Optimum Perspectives

Tackling the threat of AMR 13/11/2025
The ups and downs of ADCs – where to now? 03/11/2025
Q&A with CSO Caroline Benn discussing LoQus23's unique approach to Huntington’s disease 05/08/2025
Q&A with Professor Ali Tavassoli of Curve Therapeutics: RSC Interdisciplinary Prize winner 2025 25/06/2025
Stronger together: changing the future of muscle wasting condition 28/02/2025
How bioengineered spider silk-based proteins are changing the world 06/02/2025
How to have a perfect IPO on NASDAQ 23/01/2025
Ariceum Therapeutics: Pioneering research into next-generation radiopharmaceutical therapy targeting hard-to-treat cancers 27/11/2024
Kling Biotherapeutics: Using B cell tech to discover new targets and antibodies in cancer 21/11/2024
DISCO Pharmaceuticals looks to unlock new drugs with “surfaceome” technology 05/11/2024
© 2003-2026 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA